Results 1 to 10 of about 16,658,609 (280)
CAR T Cell Therapy for Neuroblastoma [PDF]
Frontiers in Immunology, 2018 Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall ...
Rebecca M. Richards +2 more
doaj +5 more sources
Immunological Medicine, 2021 Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj +6 more sources
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Frontiers in Immunology, 2023 Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been substantially improved with the emergence of novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies ...
Xiaomin Zhang +4 more
doaj +3 more sources
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Frontiers in Immunology, 2022 Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies.
Xiaomin Zhang +6 more
doaj +3 more sources
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
Current Issues in Molecular Biology, 2023 Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte.
Hong Yun Ma +11 more
doaj +3 more sources
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Frontiers in ImmunologyChimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging.
Yaojie Kong +4 more
doaj +3 more sources
Reactions WeeklyChimeric antigen receptor T-cell (CAR-T) therapy has rapidly reshaped the therapeutic landscape for children and adolescents with relapsed or refractory hematologic malignancies. In Brazil, the integration of CAR-T therapy into pediatric oncology practice faces unique logistical, regulatory, and socioeconomic challenges, highlighting the need for ...
Antonella Zanette +6 more
+14 more sources
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
Mediterranean Journal of Hematology and Infectious DiseasesChimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes.
Ugo Testa +4 more
doaj +3 more sources
Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
Acta Pharmaceutica Sinica BChimeric antigen receptor T (CAR-T) cell therapy as a form of adoptive cell therapy (ACT) has shown significant promise in cancer treatment, demonstrated by the FDA-approved CAR-T cell therapies targeting CD19 or B cell maturation antigen (BCMA) for ...
Dian Xiong, Haijun Yu, Zhi-Jun Sun
doaj +3 more sources
Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
Cells, 2023 T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation ...
Julia Sajman +7 more
doaj +1 more source